Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial

Abstract Aim Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Aida Mohammadi (Author), Gita Sadighi (Author), Ali Nazeri Astaneh (Author), Maryam Tajabadi‐Ebrahimi (Author), Tahereh Dejam (Author)
Format: Book
Published: Wiley, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c1bbef3bfc94427fbf9c19cea1bfa624
042 |a dc 
100 1 0 |a Aida Mohammadi  |e author 
700 1 0 |a Gita Sadighi  |e author 
700 1 0 |a Ali Nazeri Astaneh  |e author 
700 1 0 |a Maryam Tajabadi‐Ebrahimi  |e author 
700 1 0 |a Tahereh Dejam  |e author 
245 0 0 |a Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial 
260 |b Wiley,   |c 2024-06-01T00:00:00Z. 
500 |a 2574-173X 
500 |a 10.1002/npr2.12431 
520 |a Abstract Aim Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients. Methods In the present study, 70 patients (aged 18-65) with schizophrenia were recruited. Participants were randomly allocated to the placebo (n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups. Severity of disease and cognitive function (primary outcomes) were evaluated by Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MoCA) tests, respectively. Moreover, lipid profile, body mass index (BMI), gastrointestinal (GI) problems, serum C‐reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated as secondary outcomes. Results A total of 69 patients completed the study. The MoCA score was increased by 1.96 units in the probiotic‐containing supplement group compared to the placebo (p = 0.004). Also, the percentage of subjects with MoCA score ≥ 26 rose significantly in the intervention group (p = 0.031). Moreover, TC (p = 0.011), FBS (p = 0.009), and CRP (p < 0.001) significantly decreased in the supplement group compared to the placebo. Although the probiotic supplement reduced PANSS score by 2.82 units, the difference between the study groups was not statistically significant (p = 0.247). Conclusion Co‐administration of probiotics and vitamin D has beneficial effects on the improvement of cognitive function in schizophrenic patients. 
546 |a EN 
690 |a cognitive function 
690 |a probiotics 
690 |a schizophrenia 
690 |a vitamin D 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
655 7 |a article  |2 local 
786 0 |n Neuropsychopharmacology Reports, Vol 44, Iss 2, Pp 389-398 (2024) 
787 0 |n https://doi.org/10.1002/npr2.12431 
787 0 |n https://doaj.org/toc/2574-173X 
856 4 1 |u https://doaj.org/article/c1bbef3bfc94427fbf9c19cea1bfa624  |z Connect to this object online.